Related Experiment Video
Updated: Jun 8, 2026
13:19
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
S-1 is an active anticancer agent for advanced thymic carcinoma
Yusuke Okuma1, Tsuneo Shimokawa, Yusuke Takagi
1Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo 113-8677, Japan.
Lung Cancer (Amsterdam, Netherlands)
|October 19, 2010
Summary
Oral S-1 monotherapy shows promise as a salvage chemotherapy for advanced thymic carcinoma. This treatment offers a potential alternative for patients intolerant to platinum-based therapies.
Area of Science:
- Oncology
- Thoracic Surgery
- Pharmacology
Background:
- Thymic carcinoma, a rare intrathoracic malignancy, has a poor prognosis in advanced stages.
- No standard front-line chemotherapy exists for advanced thymic carcinoma.
- Efficacy of second-line or salvage chemotherapy is largely unknown.
Observation:
- Evaluated S-1 monotherapy as salvage treatment in four advanced thymic carcinoma patients.
- S-1 is an oral fluoropyrimidine agent.
- Patients had previously undergone treatment.
Findings:
- Two patients achieved partial response, two achieved stable disease.
- Median progression-free survival was 8.1 months.
- Mild hematological toxicity but significant gastrointestinal toxicity requiring discontinuation in two patients.
Implications:
- Oral S-1 monotherapy is a viable option for second-line or later chemotherapy in advanced thymic carcinoma.
- S-1 presents a potential alternative for patients unable to tolerate platinum-based treatments.
